Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Apexbio Technology LLC Repotrectinib 1802220-02-5 10mg
Supplier: Apexbio Technology LLC A465010
Repotrectinib (CAS 1802220-02-5) is a macrocyclic small molecule inhibitor of tyrosine kinases developed to overcome resistance mechanisms in non-small cell lung cancer (NSCLC) mediated by ROS1 gene mutations Its compact structure enables selective inhibition of both wild-type and solvent-front mutated ROS1 including the G2032R variant frequently associated with resistance to first-generation TKIs such as crizotinib Repotrectinib has demonstrated robust clinical activity in the TRIDENT-1 study with an objective response rate of 79% in TKI-naive and 38% in TKI-pretreated ROS1-positive NSCLC patients It serves as a valuable tool for investigating mechanisms of kinase inhibitor resistance in oncogenic ROS1-driven cancers
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?